• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer.
【24h】

Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer.

机译：酵母全葡聚糖颗粒（WGP）β-葡聚糖与抗肿瘤单克隆抗体一起治疗癌症。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Beta-glucans, biological response modifiers (BRMs) derived from the cell walls of yeast and other sources, have been demonstrated to prime leukocyte complement receptor 3 (CR3), thus enabling these cells to kill tumours opsonised with complement fragment iC3b. Many tumours activate complement via the classical pathway mediated by antitumour monoclonal antibodies (mAbs) or natural antibodies. Studies into the cellular and molecular mechanisms of action have demonstrated that orally administrated yeast beta-glucans are ingested and processed by macrophages. These macrophages secrete the active moiety that primes neutrophil CR3 to kill iC3b-opsonised tumour cells. Extensive studies in preclinical animal tumour models have demonstrated the efficacy of combined oral particulate yeast beta-glucan with antitumour mAb therapy in terms of tumour regression and long-term survival. It is proposed that the addition of beta-glucan will further improve the clinical therapeutic efficacy of antitumour mAbs in cancer patients.
机译：β-葡聚糖，一种源自酵母细胞壁和其他来源的生物反应调节剂（BRM），已被证明可引发白细胞补体受体3（CR3），从而使这些细胞能够杀死由补体片段iC3b调理的肿瘤。许多肿瘤通过抗肿瘤单克隆抗体（mAb）或天然抗体介导的经典途径激活补体。对细胞和分子作用机制的研究表明，口服施用的酵母β-葡聚糖被巨噬细胞摄取和加工。这些巨噬细胞分泌激活中性粒细胞CR3的活性部分，以杀死iC3b调理过的肿瘤细胞。在临床前动物肿瘤模型中的大量研究表明，口服抑粒酵母β-葡聚糖与抗肿瘤mAb联合治疗在肿瘤消退和长期生存方面具有疗效。提出添加β-葡聚糖将进一步改善抗肿瘤mAb在癌症患者中的临床治疗功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号